<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820715</url>
  </required_header>
  <id_info>
    <org_study_id>DA3030_DN_I (Version 3.4)</org_study_id>
    <nct_id>NCT01820715</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain</brief_title>
  <official_title>A Phase I Study of the DA-3030 Injection to Evaluate Its Safety and Explore the Efficacy for Diabetic Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is
      designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for
      Neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormal score of vital signs measured by following methods: two-sample t-test, Wilcoxon rank sum test, Paired t- test, Wilcoxon signed rank test, McNemar test, Chi-squared test, or/and Fisher's exact test</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects or Incidence with Adverse Events including Adverse Drug Event and Serious Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average pain score</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most severe pain score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overnight pain score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measuring how much the subject feels pain last night on a scale of one to ten (no pain - most severe pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>600㎍ of DA-3030 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600㎍ of DA-3030 is injected once a day, for 5 continuous days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo(a salin drip) is injected once a day, for 5 continuous days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>600㎍ of DA-3030 Injection</intervention_name>
    <arm_group_label>600㎍ of DA-3030 Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20≤ Age ≤ 70

          -  Diagnosed with Type I or Type II diabetes

          -  HbA1c ≤ 11%

          -  Patients with diabetic neuropathic pain for at least 3 months

          -  Patients corresponding to average pain level of 4 points or mor for 24 hours evaluated
             with 11-point Likert scale

        Exclusion Criteria:

          -  Neuropathic pain due to other causes

          -  Another stronger pain other than neuropathic pain

          -  Abnormality in blood pressure, weight

          -  Positive reaction in HIV, HBV or HCV

          -  A medical history of mental illness within 6 months

          -  The grade of BDI(Beck Depression Inventory) exceeds 21 points

          -  History of drug/alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoo Heon Ahn, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bong Yeon Cha, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyung Soo Ko, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Sun Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Soo Park, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choon Hee Chung, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In Joo Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>133-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

